Codexis to Offer High-Performance Enzymes for Diagnostics Markets

6 Jan 2017

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.  Codexis’ first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quarter of 2017.

Codexis to Offer High-Performance Enzymes for Diagnostics Markets

REDWOOD CITY, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.  Codexis’ first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quarter of 2017.

“Enzymes are critical to the sensitivity and reliability of NGS and PCR analyses,” said Michael Aldridge, Codexis Senior Vice President, Corporate & Strategic Development. “Historically, NGS and PCR work-flows relied on only modestly engineered enzymes.  However, as users push NGS and PCR into new, more demanding applications, such as liquid biopsy and personalized medicine samples, more capable enzymes are required. 

“Our CodeEvolver® protein engineering platform technology is able to rapidly deliver novel enzymes with dramatically enhanced performance characteristics,” Aldridge added.  “We are confident that our enzymes can improve analytical efficiency, processivity and fidelity while also reducing bias. In less than a year, our CodeEvolver® platform technology has engineered an enzyme that improves library preparation steps for NGS.”

“This has been an outstanding self-directed R&D investment for Codexis,” said John Nicols, Codexis President and Chief Executive Officer.  “Today’s announcement signifies our first effort to offer improved, proprietary Codexis enzymes to users in the established industrial enzyme market and underscores our ability to continue to develop differentiated and value-creating proteins in new enzyme markets, alongside existing applications in pharmaceutical manufacturing, biologic drug discovery and food ingredient production.”

Read More